Featured Research

from universities, journals, and other organizations

Therapeutic Vaccine Prolongs Survival And Improves Quality Of Life

Date:
May 18, 2008
Source:
American Urological Association
Summary:
A new prostate cancer vaccine may give hope to men with metastatic prostate cancer by enabling their immune systems to fight the disease. In recent years, the concept of vaccine immunotherapy for advanced prostate cancer has become increasingly high profile as research has expanded.

A new prostate cancer vaccine may give hope to men with metastatic prostate cancer by enabling their immune systems to fight the disease. Researchers from the University of Iowa presented data on the adenovirus/PSA (Ad/PSA) vaccine during the Annual Scientific Meeting of the American Urological Association in Orlando.

In recent years, the concept of vaccine immunotherapy for advanced prostate cancer has become increasingly high profile as research has expanded. Major advances in the field have contributed significantly to the discussion of this important cancer therapy as researchers explore new ways to prolong survival and improve the quality of life in patients with metastatic disease.

Prostate cancer cells produce a protein known as prostate-specific antigen (PSA). The goal of immunotherapy for metastatic disease is to manipulate the body’s immune system to identify and destroy these cancer cells throughout the body. The Ad/PSA vaccine was developed by inserting the PSA gene into bacteria and viruses and using immune-stimulatory deoxyribonucleic acid (DNA) to modulate the body’s anti-tumor response. Enabling a patient’s immune system to produce anti-antigens and attack cancer cells can improve quality of life and extend survival. Earlier studies in mice demonstrated the vaccine’s efficacy as it produced strong anti-PSA and, as a result, powerful anti-prostate cancer immunity.

This Phase I clinical trial assessed the performance of the Ad/PSA vaccine in men with measurable metastatic prostate cancer. Patients with D2 or D3 cancers (median age 71, median PSA 128 ng/ml) were treated with one of three dose levels of the vaccine and were followed with physical and clinical chemistry exams at two and three weeks and two, four, eight and 12 months. Median follow up was 12 months and median survival was 18 months.

After receiving the vaccine, at least 40 percent of patients developed immune responses to PSA, with anti-PSA antibodies produced in 42 percent of patients and anti-PSA T-cell responses in 71 percent. 57 percent of patients survived longer than predicted, with doubling time increased in 48 percent. Longest survival was 71 months – nearly six years.


Story Source:

The above story is based on materials provided by American Urological Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lubaroff DM, Konety BR, Link BK, Ratliff TL, Madsen T, Williams R: Outcomes from a phase I trial of an adenovirus/PSA vaccine for prostate cancer. J Urol, suppl., 2008; 179: 184, abstract 526. [link]

Cite This Page:

American Urological Association. "Therapeutic Vaccine Prolongs Survival And Improves Quality Of Life." ScienceDaily. ScienceDaily, 18 May 2008. <www.sciencedaily.com/releases/2008/05/080515072847.htm>.
American Urological Association. (2008, May 18). Therapeutic Vaccine Prolongs Survival And Improves Quality Of Life. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2008/05/080515072847.htm
American Urological Association. "Therapeutic Vaccine Prolongs Survival And Improves Quality Of Life." ScienceDaily. www.sciencedaily.com/releases/2008/05/080515072847.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins